Tandem Diabetes Care is shifting its operational focus towards pharmacy distribution as part of a broader strategy to improve profitability.
The company has set a target of achieving a 65% gross margin by the year 2026, indicating a significant emphasis on financial performance.
Additionally, Tandem plans to introduce the Mobi Tubeless device in 2026, which may impact its product lineup and market positioning.